Pediatric Pleural Effusion Medication

  • Author: Dagnachew (Dagne) Assefa, MD; Chief Editor: Michael R Bye, MD   more...
 
Updated: Oct 5, 2011
 

Medication Summary

The treatment of a transudative, chylous, or hemorrhagic pleural effusion involves treatment of the underlying process. Antibiotics are administered for parapneumonic effusions caused by aerobic and anaerobic organisms. Specific agents should be based on the patient's age and the types of organisms and sensitivities common in the community. Therefore, the list of antibiotics below is only a guide. More than 1 agent may be used for synergy and for polymicrobial infections. Antibiotics may be changed if the organisms and their sensitivities are identified.

Initially, administer antibiotics intravenously while a thoracostomy tube is present until some time after the child is afebrile and improving clinically; then, the IV drugs can be switched to oral medications for 2-4 weeks. Empyema usually requires prolonged antimicrobial therapy.

Antituberculous drugs for tuberculosis-associated effusion should be administered for 6-9 months. Chemotherapeutic agents are used for malignancy. Steroids are indicated for connective-tissue disorders and may be useful for tuberculosis effusion. Fibrinolytic drugs are used to lyse fibrinous strands in loculated empyemas.

Next

Antibiotics, Other

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

View full drug information

Nafcillin

 

Nafcillin is a broad-spectrum penicillin. It is used for methicillin-sensitive S aureus and is the initial therapy for suspected penicillin G–resistant streptococcal or staphylococcal infections. In severe infections, start with parenteral therapy, and change to oral therapy as the condition warrants. Because of thrombophlebitis, particularly in elderly persons, administer parenterally for only 1-2 days; change to oral therapy as indicated clinically.

View full drug information

Oxacillin

 

Oxacillin is a bactericidal antibiotic that inhibits cell-wall synthesis. It is used to treat infections caused by penicillinase-producing staphylococci. Oxacillin may be used to start therapy when a staphylococcal infection is suspected.

View full drug information

Vancomycin (Vancocin)

 

Vancomycin can be used for methicillin-resistant S aureus and for S pneumoniae. It is a potent antibiotic against gram-positive organisms and is active against Enterococcus species. Vancomycin is indicated for patients who cannot receive or whose conditions fail to respond to penicillins and cephalosporins or those with infections with resistant staphylococci. To avoid toxicity, the current recommendation is to assay vancomycin trough levels 30 minutes before the fourth dose. Use creatinine clearance (CrCl) to adjust the dose in renal impairment.

View full drug information

Penicillin G aqueous (Pfizerpen)

 

Penicillin G is used to treat S pneumoniae infection and anaerobic bacteria. It interferes with synthesis of cell-wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms.

View full drug information

Cefotaxime (Claforan)

 

Cefotaxime is a third-generation cephalosporin. It can be used for S pneumoniae or H influenzae infection. Cefotaxime arrests bacterial cell-wall synthesis, inhibiting bacterial growth.

View full drug information

Ceftriaxone (Rocephin)

 

Ceftriaxone is a third-generation cephalosporin; it can be used for S pneumoniae or H influenzae infection. Ceftriaxone arrests bacterial growth by binding to 1 or more penicillin-binding proteins.

View full drug information

Clindamycin (Cleocin)

 

Clindamycin can be used for S pneumoniae infection and anaerobes and as alternative drug for methicillin-resistant S aureus. It is also effective against aerobic and anaerobic streptococci (except enterococci). Clindamycin inhibits bacterial growth, possibly by blocking dissociation of peptidyl transfer ribonucleic acid (tRNA) from ribosomes, causing RNA-dependent protein synthesis to arrest.

View full drug information

Linezolid (Zyvox)

 

Linezolid prevents the formation of a functional 70S initiation complex, which is essential for the bacterial translation process. It is bacteriostatic against enterococci and staphylococci and bactericidal against most strains of streptococci. Linezolid is used as an alternative in patients who are allergic to vancomycin and for the treatment of vancomycin-resistant enterococci.

Previous
Next

Antitubercular Agents

Class Summary

These agents are used for the treatment of drug-susceptible tuberculosis infection. Recommendations include 6-9 months of therapy. The 6-month regimen includes either 2 months of isoniazid (INH), rifampin, and pyrazinamide once per day, followed by 4 months of INH and rifampin daily, or 2 months of INH, rifampin, and pyrazinamide daily, followed by 4 months of INH and rifampin twice weekly under directly observed therapy (DOT).

For drug-resistant tuberculosis, initial treatment should include 4 drugs until susceptibility is determined. Therapy should last 12-18 months.

View full drug information

Isoniazid

 

Isoniazid offers the best combination of effectiveness, low cost, and minor adverse effects. It is a first-line drug unless resistance or another contraindication is known. Therapeutic regimens of less than 6 months have an unacceptably high relapse rate. Coadministration of pyridoxine is recommended if peripheral neuropathies secondary to INH therapy develop. Prophylactic doses of 6-50 mg/d are recommended.

View full drug information

Rifampin (Rifadin)

 

Rifampin is for use in combination with at least 1 other anti-tuberculosis drug. It inhibits RNA synthesis in bacteria by binding to the beta subunit of DNA-dependent RNA polymerase, which in turn blocks RNA transcription. Cross-resistance may occur. Treat the patient for 6-9 months or until 6 months have elapsed from conversion to negative sputum cultures.

View full drug information

Pyrazinamide

 

This is a pyrazine analog of nicotinamide that may be bacteriostatic or bactericidal against M tuberculosis, depending on the concentration of drug attained at the site of infection. The mechanism of action is unknown. In drug-susceptible patients, administer pyrazinamide for the initial 2 months of a regimen lasting 6 months or longer. Treat drug-resistant cases with individualized regimens.

View full drug information

Streptomycin

 

Streptomycin is administered for the treatment of susceptible mycobacterial infections. It is used in combination with other anti-tuberculosis drugs (eg, INH, ethambutol, rifampin).

Previous
Next

Thrombolytics

Class Summary

Fibrinolytic drugs may lyse the fibrinous strands in loculated empyemas and thereby clear the lymphatic pores and restore pleural fluid circulation.[101, 102]

View full drug information

Alteplase (Activase, Cathflo Activase, TPA)

 

Tissue plasminogen activator binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin, thereby initiating local fibrinolysis. Alteplase's serum half-life is 4-6 minutes, but the half-life is lengthened when alteplase is bound to fibrin in a clot. Circulating plasma levels are not expected to reach pharmacologic concentrations after intrapleural administration.

Previous
 
Contributor Information and Disclosures
Author

Dagnachew (Dagne) Assefa, MD  Pediatric Pulmonologist, Respiratory Center for Children, Morristown Memorial Hospital

Dagnachew (Dagne) Assefa, MD is a member of the following medical societies: American Academy of Pediatrics, American Academy of Sleep Medicine, American College of Chest Physicians, and American Thoracic Society

Disclosure: Nothing to disclose.

Coauthor(s)

Arthur B Atlas, MD  Assistant Clinical Professor, Department of Pediatrics, University of Medicine and Dentistry of New Jersey

Arthur B Atlas, MD is a member of the following medical societies: American Academy of Pediatrics, American Academy of Sleep Medicine, American College of Chest Physicians, American Lung Association, American Thoracic Society, and Medical Society of New Jersey

Disclosure: astra zeneca Grant/research funds None

Chief Editor

Michael R Bye, MD  Professor of Clinical Pediatrics, Division of Pulmonary Medicine, Columbia University College of Physicians and Surgeons; Attending Physician, Pediatric Pulmonary Medicine, Morgan Stanley Children's Hospital of New York Presbyterian, Columbia University Medical Center

Michael R Bye, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, and American Thoracic Society

Disclosure: Nothing to disclose.

Additional Contributors

Heidi Connolly, MD Associate Professor of Pediatrics and Psychiatry, University of Rochester School of Medicine and Dentistry; Director, Pediatric Sleep Medicine Services, Strong Sleep Disorders Center

Heidi Connolly, MD is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Girish D Sharma, MD Associate Professor of Pediatrics, Rush Medical College; Director, Section of Pediatric Pulmonology and Rush Cystic Fibrosis Center, Rush University Medical Center

Girish D Sharma, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, and Royal College of Physicians of Ireland

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References

  1. Wang NS. Anatomy of the pleura. Clin Chest Med. Jun 1998;19(2):229-40. [Medline].

  2. Agostoni E, Zocchi L. Mechanical coupling and liquid exchanges in the pleural space. Clin Chest Med. Jun 1998;19(2):241-60. [Medline].

  3. Alkrinawi S, Chernick V. Pleural infection in children. Semin Respir Infect. Sep 1996;11(3):148-54. [Medline].

  4. Hardie W, Bokulic R, Garcia VF, et al. Pneumococcal pleural empyemas in children. Clin Infect Dis. Jun 1996;22(6):1057-63. [Medline].

  5. Givan DC, Eigen H. Common pleural effusions in children. Clin Chest Med. Jun 1998;19(2):363-71. [Medline].

  6. Alkrinawi S, Chernick V. Pleural fluid in hospitalized pediatric patients. Clin Pediatr (Phila). Jan 1996;35(1):5-9. [Medline].

  7. Le Monnier A, Carbonnelle E, Zahar JR, et al. Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids. Clin Infect Dis. Apr 15 2006;42(8):1135-40. [Medline].

  8. Saglani S, Harris KA, Wallis C, Hartley JC. Empyema: the use of broad range 16S rDNA PCR for pathogen detection. Arch Dis Child. Jan 2005;90(1):70-3. [Medline].

  9. Buckingham SC, King MD, Miller ML. Incidence and etiologies of complicated parapneumonic effusions in children, 1996 to 2001. Pediatr Infect Dis J. Jun 2003;22(6):499-504. [Medline].

  10. Hardie WD, Roberts NE, Reising SF, Christie CD. Complicated parapneumonic effusions in children caused by penicillin- nonsusceptible Streptococcus pneumoniae. Pediatrics. Mar 1998;101(3 Pt 1):388-92. [Medline].

  11. Quintero DR, Fan LL. Approach to pleural effusions and empyemas. Paediatr Respir Rev. 2004;5 Suppl A:S151-2. [Medline].

  12. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. Feb 2005;5(2):83-93. [Medline].

  13. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J. Mar 2006;25(3):250-4. [Medline].

  14. Eltringham G, Kearns A, Freeman R, et al. Culture-negative childhood empyema is usually due to penicillin-sensitive Streptococcus pneumoniae capsular serotype 1. J Clin Microbiol. Jan 2003;41(1):521-2. [Medline].

  15. Obando I, Munoz-Almagro C, Arroyo LA, et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis. Sep 2008;14(9):1390-7. [Medline].

  16. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. May 1 2003;348(18):1737-46. [Medline].

  17. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. Mar 2004;113(3 Pt 1):443-9. [Medline].

  18. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. Apr 12 2006;295(14):1668-74. [Medline].

  19. Li ST, Tancredi DJ. Empyema Hospitalizations Increased in US Children Despite Pneumococcal Conjugate Vaccine. Pediatrics. Nov 30 2009;[Medline].

  20. [Guideline] Balfour-Lynn IM, Abrahamson E, Cohen G, et al. BTS guidelines for the management of pleural infection in children. Thorax. Feb 2005;60 Suppl 1:i1-21. [Medline]. [Full Text].

  21. Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics. Jun 2004;113(6):1735-40. [Medline].

  22. Gonzalez BE, Hulten KG, Dishop MK, Lamberth LB, Hammerman WA, Mason EO Jr, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis. Sep 1 2005;41(5):583-90. [Medline].

  23. Freij BJ, Kusmiesz H, Nelson JD, McCracken GH Jr. Parapneumonic effusions and empyema in hospitalized children: a retrospective review of 227 cases. Pediatr Infect Dis. Nov-Dec 1984;3(6):578-91. [Medline].

  24. Bryant RE, Salmon CJ. Pleural empyema. Clin Infect Dis. May 1996;22(5):747-62; quiz 763-4. [Medline].

  25. Cowan MR, Primm PA, Scott SM, Abramo TJ, Wiebe RA. Serious group A beta-hemolytic streptococcal infections complicating varicella. Ann Emerg Med. Apr 1994;23(4):818-22. [Medline].

  26. Brook I. Microbiology of empyema in children and adolescents. Pediatrics. May 1990;85(5):722-6. [Medline].

  27. Merino JM, Carpintero I, Alvarez T, et al. Tuberculous pleural effusion in children. Chest. Jan 1999;115(1):26-30. [Medline].

  28. Kim HJ, Lee HJ, Kwon SY, et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest. May 2006;129(5):1253-8. [Medline].

  29. Cruz AT, Starke JR. Clinical manifestations of tuberculosis in children. Paediatr Respir Rev. Jun 2007;8(2):107-17. [Medline].

  30. Panitch HB, Papastamelos C, Schidlow DV. Abnormalities of the pleural space. In: Taussig LM, Landau LI, eds. Pediatric Respiratory Medicine. 1999:1178-96.

  31. Sassoon CS, Light RW. Chylothorax and pseudochylothorax. Clin Chest Med. Mar 1985;6(1):163-71. [Medline].

  32. Soto-Martinez M, Massie J. Chylothorax: diagnosis and management in children. Paediatr Respir Rev. Dec 2009;10(4):199-207. [Medline].

  33. Munoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. Jan 15 2008;46(2):174-82. [Medline].

  34. Chonmaitree T, Powell KR. Parapneumonic pleural effusion and empyema in children. Review of a 19-year experience, 1962-1980. Clin Pediatr (Phila). Jun 1983;22(6):414-9. [Medline].

  35. Mocelin HT, Fischer GB. Epidemiology, presentation and treatment of pleural effusion. Paediatr Respir Rev. Dec 2002;3(4):292-7. [Medline].

  36. Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. Jan 2010;125(1):26-33. [Medline].

  37. Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis. Feb 15 2002;34(4):434-40. [Medline].

  38. Calbo E, Diaz A, Canadell E, et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect. Sep 2006;12(9):867-72. [Medline].

  39. Desrumaux A, Francois P, Pascal C, et al. [Epidemiology and clinical characteristics of childhood parapneumonic empyemas]. Arch Pediatr. Nov 2007;14(11):1298-303. [Medline].

  40. Avansino JR, Goldman B, Sawin RS, Flum DR. Primary operative versus nonoperative therapy for pediatric empyema: a meta-analysis. Pediatrics. Jun 2005;115(6):1652-9. [Medline].

  41. Meyerovitch J, Shohet I, Rubinstein E. Analysis of thirty-seven cases of pleural empyema. Eur J Clin Microbiol. Jun 1985;4(3):337-9. [Medline].

  42. Barbas CS, Cukier A, de Varvalho CR, Barbas Filho JV, Light RW. The relationship between pleural fluid findings and the development of pleural thickening in patients with pleural tuberculosis. Chest. Nov 1991;100(5):1264-7. [Medline].

  43. Ampofo K, Byrington C. Management of Parapneumonic Empyema. Pediatr infec Dis J. 2007;26:445-446.

  44. Lazarus AA, McKay S, Gilbert R. Pleural tuberculosis. Dis Mon. Jan 2007;53(1):16-21. [Medline].

  45. Pietsch JB, Whitlock JA, Ford C, Kinney MC. Management of pleural effusions in children with malignant lymphoma. J Pediatr Surg. Apr 1999;34(4):635-8. [Medline].

  46. Forbes BA. Critical assessment of gene amplification approaches on the diagnosis of tuberculosis. Immunol Invest. Jan-Feb 1997;26(1-2):105-16. [Medline].

  47. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. Oct 1972;77(4):507-13. [Medline].

  48. Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators. Chest. Apr 1997;111(4):970-80. [Medline].

  49. Sahn, SA. Pathogenesis and clinical features of diseases associated with a low pleural fluid glucose. In: Chretien, J, Bignon, J, Hirsch, A. The Pleura in Health and Disease. New York: Marcel Dekker; 1985:267-285.

  50. Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med. Oct 1980;69(4):507-12. [Medline].

  51. Pettersson T, Klockars M, Hellstrom PE. Chemical and immunological features of pleural effusions: comparison between rheumatoid arthritis and other diseases. Thorax. May 1982;37(5):354-61. [Medline].

  52. Horowitz ML, Schiff M, Samuels J, Russo R, Schnader J. Pneumocystis carinii pleural effusion. Pathogenesis and pleural fluid analysis. Am Rev Respir Dis. Jul 1993;148(1):232-4. [Medline].

  53. Sahn SA, Willcox ML, Good JT Jr, Potts DE, Filley GF. Characteristics of normal rabbit pleural fluid: physiologic and biochemical implications. Lung. 1979;156(1):63-9. [Medline].

  54. Villena Garrido V, Ferrer Sancho J, Hernandez Blasco L, et al. [Diagnosis and treatment of pleural effusion]. Arch Bronconeumol. Jul 2006;42(7):349-72. [Medline].

  55. Yam LT. Diagnostic significance of lymphocytes in pleural effusions. Ann Intern Med. May 1967;66(5):972-82. [Medline].

  56. Adelman M, Albelda SM, Gottlieb J, Haponik EF. Diagnostic utility of pleural fluid eosinophilia. Am J Med. Nov 1984;77(5):915-20. [Medline].

  57. Kalomenidis I, Light RW. Eosinophilic pleural effusions. Curr Opin Pulm Med. Jul 2003;9(4):254-60. [Medline].

  58. [Guideline] Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax. May 2003;58 Suppl 2:ii8-17. [Medline].

  59. Lee YC, Rogers JT, Rodriguez RM, Miller KD, Light RW. Adenosine deaminase levels in nontuberculous lymphocytic pleural effusions. Chest. Aug 2001;120(2):356-61. [Medline].

  60. Greco S, Girardi E, Masciangelo R, Capoccetta GB, Saltini C. Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis. Int J Tuberc Lung Dis. Aug 2003;7(8):777-86. [Medline].

  61. Burgess LJ, Maritz FJ, Le Roux I, Taljaard JJ. Combined use of pleural adenosine deaminase with lymphocyte/neutrophil ratio. Increased specificity for the diagnosis of tuberculous pleuritis. Chest. Feb 1996;109(2):414-9. [Medline].

  62. Light RW. Clinical practice. Pleural effusion. N Engl J Med. Jun 20 2002;346(25):1971-7. [Medline].

  63. Chaignaud BE, Bonsack TA, Kozakewich HP, Shamberger RC. Pleural effusions in lymphoblastic lymphoma: a diagnostic alternative. J Pediatr Surg. Sep 1998;33(9):1355-7. [Medline].

  64. Qureshi NR, Gleeson FV. Imaging of pleural disease. Clin Chest Med. Jun 2006;27(2):193-213. [Medline].

  65. Wilson, AG. Pleura and pleural disorders. In: Armstrong P, Wilson AG, Dee P, et al,. Imaging of diseases of the chest. London: Mosby; 1995:641-716.

  66. Blackmore CC, Black WC, Dallas RV, Crow HC. Pleural fluid volume estimation: a chest radiograph prediction rule. Acad Radiol. Feb 1996;3(2):103-9. [Medline].

  67. Moskowitz H, Platt RT, Schachar R, Mellins H. Roentgen visualization of minute pleural effusion. An experimental study to determine the minimum amount of pleural fluid visible on a radiograph. Radiology. Oct 1973;109(1):33-5. [Medline].

  68. Kelbel C, Borner N, Schadmand S, et al. [Diagnosis of pleural effusions and atelectases: sonography and radiology compared]. Rofo. Feb 1991;154(2):159-63. [Medline].

  69. Hirsch JH, Rogers JV, Mack LA. Real-time sonography of pleural opacities. AJR Am J Roentgenol. Feb 1981;136(2):297-301. [Medline].

  70. Lipscomb DJ, Flower CD, Hadfield JW. Ultrasound of the pleura: an assessment of its clinical value. Clin Radiol. May 1981;32(3):289-90. [Medline].

  71. Wolek R, Mason BJ, Reeser P, Zins JH. Pleural fluid: accuracy of computed tomography in differentiating exudates from transudates. Conn Med. May 1998;62(5):259-65. [Medline].

  72. Aquino SL, Webb WR, Gushiken BJ. Pleural exudates and transudates: diagnosis with contrast-enhanced CT. Radiology. Sep 1994;192(3):803-8. [Medline].

  73. Arenas-Jimenez J, Alonso-Charterina S, Sanchez-Paya J, et al. Evaluation of CT findings for diagnosis of pleural effusions. Eur Radiol. 2000;10(4):681-90. [Medline].

  74. Donnelly LF, Klosterman LA. CT appearance of parapneumonic effusions in children: findings are not specific for empyema. AJR Am J Roentgenol. Jul 1997;169(1):179-82. [Medline].

  75. Jaffe A, Calder AD, Owens CM, Stanojevic S, Sonnappa S. Role of routine computed tomography in paediatric pleural empyema. Thorax. Oct 2008;63(10):897-902. [Medline].

  76. Calder A, Owens CM. Imaging of parapneumonic pleural effusions and empyema in children. Pediatr Radiol. Jun 2009;39(6):527-37. [Medline].

  77. Donnelly LF, Klosterman LA. The yield of CT of children who have complicated pneumonia and noncontributory chest radiography. AJR Am J Roentgenol. Jun 1998;170(6):1627-31. [Medline].

  78. Calder A, Owens CM. Imaging of parapneumonic pleural effusions and empyema in children. Pediatr Radiol. Jun 2009;39(6):527-37. [Medline].

  79. Jaffe A, Balfour-Lynn IM. Management of empyema in children. Pediatr Pulmonol. Aug 2005;40(2):148-56. [Medline].

  80. Light RW, Rodriguez RM. Management of parapneumonic effusions. Clin Chest Med. Jun 1998;19(2):373-82. [Medline].

  81. Teixeira LR, Sasse SA, Villarino MA, Nguyen T, Mulligan ME, Light RW. Antibiotic levels in empyemic pleural fluid. Chest. Jun 2000;117(6):1734-9. [Medline].

  82. Thys JP, Vanderhoeft P, Herchuelz A, Bergmann P, Yourassowsky E. Penetration of aminoglycosides in uninfected pleural exudates and in pleural empyemas. Chest. Mar 1988;93(3):530-2. [Medline].

  83. Thomson AH, Hull J, Kumar MR, et al. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax. Apr 2002;57(4):343-7. [Medline].

  84. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. Mar 3 2005;352(9):865-74. [Medline].

  85. Barbato A, Panizzolo C, Monciotti C, et al. Use of urokinase in childhood pleural empyema. Pediatr Pulmonol. Jan 2003;35(1):50-5. [Medline].

  86. Kilic N, Celebi S, Gurpinar A, et al. Management of thoracic empyema in children. Pediatr Surg Int. Jan 2002;18(1):21-3. [Medline].

  87. Kornecki A, Sivan Y. Treatment of loculated pleural effusion with intrapleural urokinase in children. J Pediatr Surg. Oct 1997;32(10):1473-5. [Medline].

  88. Krishnan S, Amin N, Dozor AJ, Stringel G. Urokinase in the management of complicated parapneumonic effusions in children. Chest. Dec 1997;112(6):1579-83. [Medline].

  89. Sonnappa S, Cohen G, Owens CM, et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med. Jul 15 2006;174(2):221-7. [Medline].

  90. St Peter SD, Tsao K, Spilde TL, et al. Thoracoscopic decortication vs tube thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial. J Pediatr Surg. Jan 2009;44(1):106-11; discussion 111. [Medline].

  91. Laisaar T, Pullerits T. Effect of intrapleural streptokinase administration on antistreptokinase antibody level in patients with loculated pleural effusions. Chest. Feb 2003;123(2):432-5. [Medline].

  92. Subramaniam R, Joseph VT, Tan GM, Goh A, Chay OM. Experience with video-assisted thoracoscopic surgery in the management of complicated pneumonia in children. J Pediatr Surg. Feb 2001;36(2):316-9. [Medline].

  93. [Best Evidence] Kurt BA, Winterhalter KM, Connors RH, Betz BW, Winters JW. Therapy of parapneumonic effusions in children: video-assisted thoracoscopic surgery versus conventional thoracostomy drainage. Pediatrics. Sep 2006;118(3):e547-53. [Medline].

  94. Padman R, King KA, Iqbal S, Wolfson PJ. Parapneumonic effusion and empyema in children: retrospective review of the duPont experience. Clin Pediatr (Phila). Jul 2007;46(6):518-22. [Medline].

  95. Aziz A, Healey JM, Qureshi F, et al. Comparative analysis of chest tube thoracostomy and video-assisted thoracoscopic surgery in empyema and parapneumonic effusion associated with pneumonia in children. Surg Infect (Larchmt). Jun 2008;9(3):317-23. [Medline].

  96. Kim BY, Oh BS, Jang WC, et al. Video-assisted thoracoscopic decortication for management of postpneumonic pleural empyema. Am J Surg. Sep 2004;188(3):321-4. [Medline].

  97. Petrakis IE, Kogerakis NE, Drositis IE, et al. Video-assisted thoracoscopic surgery for thoracic empyema: primarily, or after fibrinolytic therapy failure?. Am J Surg. Apr 2004;187(4):471-4. [Medline].

  98. Gates RL, Caniano DA, Hayes JR, Arca MJ. Does VATS provide optimal treatment of empyema in children? A systematic review. J Pediatr Surg. Mar 2004;39(3):381-6. [Medline].

  99. Chan PW, Crawford O, Wallis C, Dinwiddie R. Treatment of pleural empyema. J Paediatr Child Health. Aug 2000;36(4):375-7. [Medline].

  100. McLaughlin FJ, Goldmann DA, Rosenbaum DM, et al. Empyema in children: clinical course and long-term follow-up. Pediatrics. May 1984;73(5):587-93. [Medline].

  101. Walker CA, Shirk MB, Tschampel MM, Visconti JA. Intrapleural alteplase in a patient with complicated pleural effusion. Ann Pharmacother. Mar 2003;37(3):376-9. [Medline].

  102. Wells RG, Havens PL. Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. Radiology. Aug 2003;228(2):370-8. [Medline].

 
Previous
Next
 
Upright chest radiograph in a 3-year-old child with dyspnea and fever obtained 1 day before the development of the pleural effusion reveals pneumonia on the left side.
Upright chest radiograph in a 3-year-old child with dyspnea and fever reveals a large opacity on the left, with obliteration of the left costophrenic angle and a fluid stripe.
Left lateral decubitus image in a 3-year-old child with dyspnea and fever reveals minimal layering of the fluid, which indicates a loculated effusion.
Upright posteroanterior chest radiograph of a child with a right-sided pleural effusion.
Lateral view in a child with right-sided pleural effusion reveals a pleural effusion and a fluid level.
Right lateral decubitus radiograph in a child with a right-sided pleural effusion. Image reveals partial layering of the fluid in the right side.
Posteroanterior view in a patient with reaccumulated pleural effusion in the left side of the chest.
Left lateral view in a patient with reaccumulated pleural effusion on the left side of the chest reveals layering of the effusion.
Anteroposterior view of the chest reveals a large chylothorax on the right side of the chest in a neonate.
Anteroposterior view in a neonate reveals reaccumulation of the chylothorax in the right hemithorax after a chest tube has been removed.
Right lateral decubitus radiograph in a neonate reveals layering of the chylothorax effusion after a chest tube has been removed.
Ultrasonogram of the pleural effusion in a 3-year-old child with dyspnea and fever reveals many septa (arrowheads) and several large, loculated portions of fluid (arrows).
Ultrasonogram of the effusion in a 3-year-old child with dyspnea and fever reveals several fluid loculations (arrows) separated by septa (arrowheads). The lung is seen under the effusion.
CT scan of the chest in a 3-year-old child with dyspnea and fever reveals a left-sided effusion and underlying parenchymal infiltrate and atelectasis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.